• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate
【24h】

Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate

机译：脑膜炎奈瑟菌C群血清多糖和B群血清外膜囊泡结合物为二价脑膜炎双球菌疫苗候选药物

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neisseria meningitidis serogroup C polysaccharide (PS C) was conjugated to serogroup B outer membrane vesicles (OMV) in order to test the possibility of obtaining a bivalent group B and C meningococcus vaccine. The conjugate and controls were injected intraperitoneally into groups of ten mice with boosters on days 14 and 28 after the primary immunization. The following groups were used as control: (i) PS C; (ii) PS C plus OMV; (iii) OMV; and (iv) saline. The serum collected on days 0, 14, 28 and 42 were tested by enzyme-linked immunosorbent assay (ELISA) for PS C and OMV, and by complement mediated bactericidal assay against serogroups B and C. ELISA for PS C as well as bactericidal titres against serogroup C meningococci of the conjugated vaccine increased eight-fold (ELISA) and 32 fold (bactericidal) after 42 days in comparison with the PS C control group. ELISA for OMV and bactericidal titre against serogroup B meningococci of the conjugate showed no significant difference in comparison with the OMV containing controls. Furthermore, Western Blot assay of the conjugate immune serum did not bind OMV class four protein which is related to the complement dependent antibody suppressor. The results indicate that the PS C-OMV conjugate could be a candidate for a bivalent vaccine toward serogroups B and C meningococci.
机译：将脑膜炎奈瑟氏球菌血清C群多糖（PS C）与B组血清外膜囊泡（OMV）偶联，以测试获得B和C组二价脑膜炎球菌疫苗的可能性。在初次免疫后第14天和28天，将结合物和对照腹膜内注射入十只具有加强免疫力的小鼠组。以下组用作对照：（i）PS C; （ii）PS C加OMV; （iii）OMV; （iv）盐水。在0、14、28和42天收集的血清通过酶联免疫吸附测定（ELISA）检测PS C和OMV，并通过补体介导的针对血清群B和C的杀菌测定进行检测。ELISA检测PS C和杀菌滴度与PS C对照组相比，结合疫苗对C血清群脑膜炎球菌的抵抗力在42天后增加了8倍（ELISA）和32倍（杀菌）。与结合物的OMV相比，结合物的血清B型脑膜炎球菌的OMV和杀菌滴度的ELISA结果没有显着差异。此外，缀合物免疫血清的蛋白质印迹法不结合与补体依赖性抗体抑制剂相关的OMV 4类蛋白。结果表明，PS C-OMV偶联物可能是针对B和C型脑膜炎球菌血清的二价疫苗的候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号